ReportGemReportGem 中文

PUBLIC COMPANY RESEARCH HUB

LLY.N (LLY.N) Foreign Research Coverage

A focused collection of foreign research coverage for LLY.N, organized by institution and publication date for faster discovery.

Evidence documents3
Filings0
Meetings0
Research3
Displayed research share100%
Latest evidence2026-08-05

Foreign research

Eli Lilly & Co.: 2Q26 First Take2026-08-05 · Morgan Stanley

M Update August 5, 2026 11:57 AM GMT Eli Lilly & Co. | North America Morgan Stanley & Co. LLC Terence C Flynn, Ph.D. Equity Analyst 2Q26 First Take Alexander Yevdokimov, Ph.D. Research Associate LLY posted a top and bottom line beat vs. cons; Mounjaro, …

Eli Lilly & Company Another Strong Quarter, Continue to See Upside from Here2026-08-05 · JPMorgan

J P M O R G A N North America Equity Research 05 August 2026 Eli Lilly & Company Another Strong Quarter, Continue to See Upside from Here Exiting LLY’s 2Q results and our catch-up with the company, we continue to see …

Eli Lilly & Company 2Q26 First Take: Another Significant Beat/Raise2026-08-05 · JPMorgan

J P M O R G A N North America Equity Research 05 August 2026 Eli Lilly & Company 2Q26 First Take: Another Significant Beat/Raise This morning, LLY reported another qtrly beat (again driven by Mounjaro/ Zepbound) and raised guidance by $2.5bn at the midpoint.…

Questions this evidence can help answer

  • What changed in the latest research coverage of LLY.N?
  • Which operating and valuation themes recur across institutions?
  • Which claims should be checked against company primary-source evidence?
Research this company with AI